DiaMedica Therapeutics (NASDAQ:DMAC) Receives Buy Rating from HC Wainwright

DiaMedica Therapeutics (NASDAQ:DMAC)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 74.80% from the company’s current price.

A number of other research firms have also recently issued reports on DMAC. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, DiaMedica Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC traded up $0.21 during midday trading on Tuesday, reaching $6.87. 31,613 shares of the stock were exchanged, compared to its average volume of 203,553. DiaMedica Therapeutics has a 12 month low of $4.63 and a 12 month high of $10.42. The company has a market capitalization of $369.89 million, a price-to-earnings ratio of -9.69 and a beta of 1.01. The business has a 50-day simple moving average of $6.61 and a two-hundred day simple moving average of $6.95.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Equities research analysts expect that DiaMedica Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors have recently made changes to their positions in DMAC. Russell Investments Group Ltd. acquired a new position in DiaMedica Therapeutics during the third quarter worth $27,000. China Universal Asset Management Co. Ltd. bought a new position in DiaMedica Therapeutics in the fourth quarter valued at $29,000. Bank of America Corp DE increased its stake in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after buying an additional 8,274 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at $34,000. Finally, JPMorgan Chase & Co. bought a new stake in DiaMedica Therapeutics during the 2nd quarter worth about $49,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.